Table of Contents Table of Contents
Previous Page  716 / 812 Next Page
Information
Show Menu
Previous Page 716 / 812 Next Page
Page Background

S712

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805

EV1136

Neurological symptoms in

schizophrenia: A case report

S. Benavente López

1 ,

, N. Salgado Borrego

2

,

M.I. de la Hera Cabero

3

, I. O˜noro Carrascal

3

, L. Flores

3

,

R. Jiménez Rico

3

1

Hospital Universitario 12 de Octubre, Psychiatry, Madrid, Spain

2

Hospital Dr. Rodríguez Lafora, Psychiatry, Madrid, Spain

3

Centro San Juan de Dios Ciempozuelos, Psychiatry, Madrid, Spain

Corresponding author.

Introduction

Patients with epilepsy and schizophrenia could

present atypical clinical presentationswith neurological symptoms

that are not frequently presented in schizophrenia.

Case Report

We report the case of a 41-year-old male who

was diagnosed of schizophrenia and was admitted into a long-

stay psychiatric unit. He started at 33 years old with a depressive

disorder. After prescribing venlafaxine, symptoms did not remit

and the patient started to present apathy, anhedony, impover-

ished speech, social isolation and blunted affect. Then, the patient

started to present behavioral disturbances consisted in regressive

behavior, aggressive behavior, inappropriate language, echolalia,

sexual disinhibition, impulsivity, worsening of executive func-

tions and soliloquies. A neurological study was made with CT

scan and electroencephalography, and no evidences of neurologi-

cal abnormalities were found. After that, clozapine was prescribed,

with an improvement of some symptoms like apathy, anhedony

and aggressive behavior, but persisting the impulsivity, regres-

sive behavior, inappropriate language, sexual disinhibition and

echolalia.

Discussion

Patients with schizophrenia and epilepsy could not

respond appropriately to antipsychotic drugs. In this patient,

the psychiatric symptoms more frequently seen in schizophrenia

responded well to clozapine, but neurological symptoms did not

improve with the standard treatment, causing a severe disability to

the patient that was the main reason for his prolonged admission.

Conclusions

It is recommended to make a detailed neurological

exploration in all psychiatric patients, in order to explore atypical

symptoms and comorbidities that could reveal new diagnosis and

therapeutic objectives.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2121

EV1137

Obsessive symptoms in schizophrenia:

A case report

S. Benavente López

1 ,

, N. Salgado Borrego

2

,

M.I. de la Hera Cabero

3

, I. O˜noro Carrascal

3

, L. Flores

3

,

R. Jiménez Rico

3

1

Hospital Universitario 12 de Octubre, Psychiatry, Madrid, Spain

2

Hospital Dr. Rodríguez Lafora, Psychiatry, Madrid, Spain

3

Centro San Juan de Dios Ciempozuelos, Psychiatry, Madrid, Spain

Corresponding author.

Introduction

Schizophrenia could be presented with obsessive

thoughts or an obsessive-compulsive disorder. It is known that

some antipsychotics like clozapine could cause obsessive symp-

toms or worsen them.

Case Report

We report the case of a 53-year-old male who

was diagnosed of schizophrenia. The patient was admitted into

a long-stay psychiatric unit due to the impossibility of outpa-

tient treatment. He presented a chronic psychosis consisted in

delusions of reference, grandiose religious delusions, and auditory

pseudohallucinations. He often presented behavioral disturbances

consisted in auto and heteroaggressive behavior, being needed the

physical restraint. Various treatments were used, including cloza-

pine, but obsessive and ruminative thoughts went worse. Because

of that, clozapine dose was lowed, and it was prescribed sertra-

line and clomipramine. With this treatment the patient presented

a considerable improvement of his symptoms, ceasing the auto

and heteroaggressive behavior, presenting a better mood state, and

being possible the coexistencewith other patients. Psychotic symp-

toms did not disappeared, but the emotional and behavioral impact

caused by them was lower.

Discussion

This case report shows howa patientwith schizophre-

nia could present severe behavioral disturbances due to obsessive

symptoms. If obsessive symptoms are presented, clozapine must

be at the minimum effective dose and antidepressants with a good

antiobsessive profile.

Conclusions

Obsessive symptoms could be presented as a part

of schizophrenia. Clozapine could worsen this symptoms and it is

necessary to adjust its dose to the minimum effective dose.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2122

EV1138

Treatment of schizophrenia with

aripiprazole may contribute to

improved functions

A. Björner

1 ,

, N. Erixon-Lindroth

2

, S. Öberg Jansdotter

3

,

A. Flatla

4

1

Gothenburgh, Sweden

2

Otsuka Pharmaceuticals, Scandinavia, Stockholm, Sweden

3

Bristol-Myers Squibb at time of study, Stockholm, Sweden

4

Bristol-Myers Squibb, Oslo, Norway

Corresponding author.

Introduction

The goals with modern treatment of schizophrenia

are to achieve remission of clinical symptoms, prevent relapse, and

to restore the patients’ functions.

Objectives/aims

The objective of this study was to investigate the

impact of treatment with the partial dopamine agonist aripiprazole

on functions, measured as time spent forwork or studies, inpatients

with schizophrenia or schizoaffective disorder.

Methods

Retrospective data on employment and study activ-

ities were collected for all patients between 18–65 years with

schizophrenia or schizoaffective disorder at an open care psychosis

clinic in Sweden (

n

= 104). Possible impact of treatment with arip-

iprazole and of other variables, such as age, gender, and disease

severity, was analysed.

Results

Among patients who worked or studied at Day of admis-

sion (

n

= 36), the probability of maintaining or increasing time for

work or studies was significantly higher in patients treated with

aripiprazole compared with patients who were not (88% versus

53%;

P

= 0.020). This difference remained significant after control-

ling for severity of symptoms, age and sex. A secondary analysis,

including all patients (independent of work or study status at Day

of admission) also showed a significant difference in favour of arip-

iprazole (53% versus 26%,

P

= 0.005).

Conclusions

The results indicate that patients treated with arip-

iprazole (monotherapy or add-on) have higher probability of

maintaining functional capacity. A plausible explanation might be

aripiprazole’s favourable effect on cognitive functions.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2123